| Title |
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients
|
|---|---|
| Published in |
Clinical and Translational Oncology, January 2018
|
| DOI | 10.1007/s12094-017-1829-5 |
| Pubmed ID | |
| Authors |
J. Garde-Noguera, P. Martin-Martorell, M. De Julián, J. Perez-Altozano, C. Salvador-Coloma, J. García-Sanchez, A. Insa-Molla, M. Martín, X. Mielgo-Rubio, S. Marin-Liebana, A. Blasco-Cordellat, S. Blasco-Molla, R. Gironés, D. Marquez-Medina, F. Aparisi, M. C. Bas Cerda, S. Macia-Escalante, A. Sánchez, O. Juan-Vidal |
| Abstract |
Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need. Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry. A total of 175 patients were included. Median age was 61.5 years, 73.1% were men, 77.7% were ECOG-PS 0-1, and 86.7% were included with stage IV disease. Histology was non-squamous in 77.1%. Sixty-five received nivolumab in second line (37.1%). Thirty-eight patients had brain metastasis (22%), and 39 (22.3%) liver metastasis and 126 (72%) had more than one metastatic location. The ORR was 15.7% with median Progression free survival (PFS) 2.8 months and median OS 5.81 months. Stage III vs IV and time since the beginning of the previous line of treatment ≥ 6 vs < 6 months were associated with better response. PS 2, time since the previous line of treatment < 6 vs ≥ 6 months, and more than one metastatic location were independently associated with shorter OS in multivariable analysis (7.8 vs 2.7 months, 11.2 vs 4.6 months, and 9.4 vs 5.1 month). Finally, time since the previous treatment < 6 vs ≥ 6 months and more than one metastatic location were independently associated with shorter PFS in multivariable analysis (4.3 vs 2.3 months and 4.7 vs 2.3 months). Poor PS, short period of time since the previous treatment, and more than one metastatic location were associated with poorer prognostic. |
X Demographics
The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 5 | 38% |
| Venezuela, Bolivarian Republic of | 1 | 8% |
| Portugal | 1 | 8% |
| Unknown | 6 | 46% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 54% |
| Practitioners (doctors, other healthcare professionals) | 6 | 46% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 80 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 11% |
| Student > Master | 9 | 11% |
| Student > Doctoral Student | 9 | 11% |
| Student > Bachelor | 9 | 11% |
| Researcher | 7 | 9% |
| Other | 18 | 23% |
| Unknown | 19 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 48% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 6% |
| Nursing and Health Professions | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 1 | 1% |
| Veterinary Science and Veterinary Medicine | 1 | 1% |
| Other | 4 | 5% |
| Unknown | 28 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 February 2018.
All research outputs
#4,612,785
of 23,018,998 outputs
Outputs from Clinical and Translational Oncology
#193
of 1,321 outputs
Outputs of similar age
#103,002
of 441,261 outputs
Outputs of similar age from Clinical and Translational Oncology
#5
of 19 outputs
Altmetric has tracked 23,018,998 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,321 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,261 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.